VPC
ITOS

Vestal Point Capital’s iTeos Therapeutics ITOS Stock Holding History

Vestal Point Capital’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-900,000
Closed -$5.37M – 79
2025
Q1 		$5.37M Hold
900,000
– – 0.38% 44
2024
Q4 		$6.91M Sell
900,000
-125,000
-12% -$1.07M 0.41% 50
2024
Q3 		$10.5M Sell
1,025,000
-725,000
-41% -$11.1M 0.79% 33
2024
Q2 		$26M Buy
+1,750,000
New +$25.1M 1.94% 16

Other funds holding ITOS

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vestal Point Capital's ITOS Position: Q2 2025 in Review

Vestal Point Capital sold out of iTeos Therapeutics (ITOS) in Q2 2025, closing a stake of 900,000 shares — an estimated $5.37M sold.

Vestal Point Capital first reported a position in ITOS in Q2 2024 and held it in 4 quarters. The position peaked at $26M in Q2 2024. 137 funds tracked by Wall St. Rank hold ITOS as of Q2 2025.

  • Vestal Point Capital reported no remaining iTeos Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Vestal Point Capital sold 900,000 iTeos Therapeutics shares in Q2 2025, an estimated $5.37M.
  • Vestal Point Capital first reported a position in iTeos Therapeutics in Q2 2024 and held it in 4 quarters.
  • Vestal Point Capital's iTeos Therapeutics position peaked at $26M in Q2 2024.
  • 137 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2025.

Based on Vestal Point Capital's 13F filing for Q2 2025, filed 14 Aug 2025.